Antonella Bugatti
Brescia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications
A broad-spectrum anti-angiogenic tetrapeptide regresses diabetic retinopathy through β-arrestin-1 binding and prevention of Akt phosphorylation.
Journal: Pharmacological research
Published: June 16, 2025
Heparan sulfate proteoglycans remodel SARS-CoV-2 spike conformation to allow integrin interaction and infection of endothelial cells.
Journal: Frontiers in cellular and infection microbiology
Published: December 27, 2024
A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 20, 2024
Molecular mechanisms behind the generation of pro-oncogenic HIV-1 matrix protein p17 variants.
Journal: The Journal of general virology
Published: April 30, 2024
The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5 Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung Microvascular Endothelial Cells.
Journal: Viruses
Published: December 20, 2022
Emergence of S gene-based quasispecies explains an optimal adaptation of Omicron BA.5 subvariant in the immunocompetent vaccinated human host.
Journal: Journal of medical virology
Published: July 27, 2022
HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 28, 2022
SARS-CoV-2 Infects Human ACE2-Negative Endothelial Cells through an αvβ3 Integrin-Mediated Endocytosis Even in the Presence of Vaccine-Elicited Neutralizing Antibodies.
Journal: Viruses
Published: February 11, 2022
Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions.
Journal: Cell death & disease
Published: January 03, 2022
Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants.
Journal: Cell death & disease
Published: December 13, 2021
Last Updated: 09/26/2026